Genetic discrimination

Last updated

Genetic discrimination occurs when people treat others (or are treated) differently because they have or are perceived to have a gene mutation(s) that causes or increases the risk of an inherited disorder. It may also refer to any and all discrimination based on the genotype of a person rather than their individual merits, including that related to race, although the latter would be more appropriately included under racial discrimination. Some legal scholars have argued for a more precise and broader definition of genetic discrimination: "Genetic discrimination should be defined as when an individual is subjected to negative treatment, not as a result of the individual's physical manifestation of disease or disability, but solely because of the individual's genetic composition." [1] Genetic Discrimination is considered to have its foundations in genetic determinism and genetic essentialism, [2] and is based on the concept of genism, i.e. distinctive human characteristics and capacities are determined by genes. [3]

Contents

Genetic discrimination takes different forms depending on the country and the protections that have been taken to limit genetic discrimination, such as GINA in the United States that protects people from being barred from working or from receiving healthcare as a result of their genetic makeup. [4] The umbrella of genetic discrimination includes the notion of informed consent, which refers to an individual's right to make a decision about their participation in research with complete comprehension of the research study. [5]

Within the United States, genetic discrimination is an ever-evolving concept that remains prominent across different domains. Emerging technology such as direct-to-consumer genetic tests have allowed for broad genetic health information to be more accessible to the public but raises concerns about privacy. In addition, the COVID-19 pandemic has exacerbated difficulties of those with genetic conditions as they have faced discrimination within the U.S. healthcare system.

The idea of genetic discrimination has been combated since the 1947 Nuremberg Code that was created shortly after WWII, during which thousands of racialized and disabled victims died in tests conducted in Germany. [5] Since then, new issues of racialized genetic discrimination have come to light involving sharing of genetic information to genomic biobanks and subsequent novel treatments. Many countries are still developing policies to combat genetic discrimination in science, law, and everyday life. [6]

United States

On May 21, 2008, George W. Bush signed the Genetic Information Nondiscrimination Act, protecting individuals from genetic discrimination in health insurance and employment. H.R. 493 - Genetic Information Nondiscrimination Act (GINA) (27946508696).jpg
On May 21, 2008, George W. Bush signed the Genetic Information Nondiscrimination Act, protecting individuals from genetic discrimination in health insurance and employment.

There are multiple legal protections in place in the United States, such as Genetic Information Nondiscrimination Act (GINA), the Americans with Disabilities Act (ADA), and the Affordable Care Act (ACA), which all help to prevent genetic discrimination in the workplace, public services, and provide some insurance protection. [8] Therefore, by law, those with genetic conditions are protected from possible discrimination and have a right to receive equitable care. [8]

Genetic discrimination is illegal in the U.S. after passage of the Genetic Information Nondiscrimination Act (GINA) on May 21, 2008. [9] It was signed into law by President George W. Bush, and passed in the US Senate by a vote of 95–0 and in the House of Representatives by 414–1. [10] The legislation bars employers from using individuals' genetic information when making hiring, firing, job placement, or promotion decisions. [4] GINA also protects individuals from genetic discrimination in healthcare; [11] however, GINA itself does not define what genetic information is, leaving it up for debate. [12] Prior to the 2008 GINA Act, individuals could be denied insurance, either partially or fully, based on genetic tests they had received. [13]

Although it was passed in 2008 there were 201 cases that cited GINA in 2010 and 333 in 2014. It was not until 2013 that a company actually faced penalties under GINA. [14]

Health insurance discrimination

In 2008, The New York Times reported that some individuals avoid genetic testing out of fear that it will would impede their ability to purchase insurance or find a job. They also reported that evidence of actual discrimination was rare. [15] In November 2016 insurance company GWG Life was found to be collecting saliva samples in order to offer lower rates to people who are epigenetically healthier than others of their age. While this is positive discrimination, this does suggest future potential classification of clients by genetic data. [16]

While the 2008 GINA Act does protect against genetic discrimination pertaining to health insurance, it does not protect against genetic discrimination under other forms of insurance, such as life, disability or long-term care insurance. Therefore, patients are enjoying less protection against genetic discrimination in comparison with other peer countries, such as France, Switzerland, Australia and the United Kingdom. [17] Additionally, 2008 GINA offers no protection for home/mortgage insurance or when an employer has 15 or less employees. Excluded from the Act are also parties who are covered under Veterans Health Administration or Indian Health Services. [18] Because a variety of medical tests serve as proxies for genetic information, proponents of insurer access to genetic information argue that it does not require specific limiting legislation. [12] However, this represents an important problem for recruiting participants to medical research according to other scholars stressing that protecting American against discrimination may only happen with the advent of a voluntary moratorium by the insurance industry. [17]

Direct-to-consumer genetic testing

Background

Direct-to-consumer genetic testing was first offered in 1997 by GeneTree, a now defunct family history website. A genetic test is considered a direct-to-consumer test if it is presented to the consumer separate from a health care provider. [19] These tests are easily accessible on the market and popularized by companies such as 23andMe and Ancestry.com. These genetic kits are expensive and disproportionately serve wealthy individuals. As a result, when the data collected from testing is sold to research companies, it represents a biased sample of the population. [20] The Food and Drug Administration additionally halted all 23andMe marketing in 2013 over unsubstantiated claims 23andMe made regarding disease diagnosis and prevention. After an investigation, the FDA approved 23andMe to begin carrier screening in 2015 and to resume genetic health risk screening in 2017. [21] This has led the way for an expansion of the market of direct-to-consumer genetic tests.

Controversy

The shortage of knowledge about and awareness of direct-to-consumer genetic testing is one of the contributors to the previously limited purchasing of this kind of service. [22] As technology has progressed, genetic testing has become a more wide scale practice, potentially affecting the privacy of consumers as a result. [23] While some providers of DTC testing destroy the samples after giving the consumer their data, others keep the samples for future data use. [24] The way in which samples that are sent to DTC genetic testing companies are used after analysis is an important point of ethical controversy, as many worry that the creation of biobanks form DTC data creates increased possibility for genetic discrimination. [24] Genomic information is playing an increasingly important role in medical practice and progress. As DTC companies continue to grow, a large obstacle they face is creating a sense of trust with the public in promising to uphold nondiscrimination standards as consumer health data is not currently regulated. [25] Some argue that the clinical utility of results from DTC tests is extremely limited and thus the risk of genetic discrimination is not worth the utility of DTC tests. However, DTC companies argue that the lack of regulation for these companies equip them for a unique position to provide important health related data for contributions to personalized medicine. [26]

One current example of this ethical controversy was demonstrated in the 2018 announcement of 23andMe's partnership with the pharmaceutical company GlaxoSmithKline. In this deal, GlaxoSmithKline purchased a $300 million stake in 23andMe and in return 23andMe would allow the pharmaceutical company access to its biobank of genomic data for their pharmaceutical research. [27] While these companies made this announcement in celebration of the opportunity for progress in pharmacogenomics and drug development, others were wary of the possible breaches of privacy that selling customer's personal genomic data may entail. Privacy concerns include incidental data sharing to third-party companies, such as insurance companies or employers. Privacy concerns with genetic information also extend to family members of DTC customers, having similar genetic make-up to their family member who did consent to data sharing, although these individuals did not consent themselves. [28] GINA protects against genetic discrimination in health insurance and employment; however, there are circumstances of exception. For example, GINA does not protect individuals from genetic discrimination in life insurance, disability insurance, and long-term care or employees in companies with fewer than 15 individuals or in the military. [29] DTC companies are not regulated in the same way as physician genetic testing and the disclaimers of data sharing in DTC companies is not as clear as medical biobanks, such as the All of Us project sponsored by the NIH. [27] However, this does not necessarily mean that the intentions of DTC companies are nefarious. According to a qualitative study published in the Journal of Personalized Medicine, these companies can prevent the feared genetic discrimination from privacy breaches by advocating for updated policy to regulate data privacy and being intentional about only sharing genetic information to sources who intend to contribute to medical discovery with the appropriate ethical standards. [25]

Genetic discrimination during COVID-19

COVID-19, or a coronavirus labeled SARS-CoV-2, is a highly-transmittable, respiratory virus first identified in Wuhan, China, in December 2019. The virus' global spread caused the COVID-19 pandemic. [30] Some research suggests that genetic conditions are among the causes of co-morbid conditions that lead to more severe COVID-19 symptoms, such as death. [31] [32] [33]

Early in the pandemic, many regions experienced shortages of medical resources like PPE and ventilators. [34] Due to the high volume of COVID-19 cases, hospital systems enacted triage protocols to direct the use of limited resources. [35] Some hospitals were accused of enacting discriminatory triage protocols which excluded those with genetic conditions, such as in Tennessee, where those with spinal muscular atrophy, an autosomal recessive disease, or other disabilities were prevented from receiving ventilators or other scarce resources. [36] [37] [ failed verification ] In other states, like Washington and Alabama, hospitals were accused of broader discriminatory allocation policies which prevented larger groups of individuals with genetic conditions under categorizations of chronic conditions or intellectual disabilities from receiving life-saving treatments, such as ventilators. [38] [39] [40] Many advocacy groups raised complaints about these triage protocols to the Department of Health and Human Services Office of Civil Rights, and after the complaints the guidelines were removed. [36]

Some commentators point to these instances as evidence that there are gaps among existent legal protections, like GINA, which may leave room for discrimination in long-term care and disability insurance, or the ADA, which more so covers ongoing disabilities, rather than susceptibility to conditions. [8] [41] Additionally conversations have turned to how to protect DNA and genetic privacy during a pandemic like COVID-19. According to Hollenstein et al., in a preprint of their research on preserving genetic privacy, they address the possible issue of mass-scale detections and numerous samples being collected through COVID-19 tests and contact-tracing and what that means in terms of who then has access or owns this genetic information. [42] While the exact solutions or changes to be made remain unknown, some solutions could possibly arise from research into equity-first preemption frameworks, which could help eliminate inequities in access to proper healthcare. [43]

Canada

The Genetic Non-Discrimination Act received Royal Assent and became law in Canada on May 4, 2017. [44] It introduced amendments to the Canadian Human Rights Act and Canada Labour Code that prohibit genetic discrimination in employment and accommodations within federally regulated industries, and also introduced criminal penalties for entities requiring individuals to undergo genetic testing as a condition for the provision of goods or services, or as a condition for entering or continuing a contract. [44] The Act also forbids anyone from refusing to enter into a goods or services agreement with another person on the grounds that that person has refused to disclose the results of an already completed genetic test. Violations are punishable by fines of up CA$1 million and/or imprisonment of up to five years. Accordingly, one effect of the legislation is to prohibit insurance providers from demanding that a prospective client undergo a genetic test—or to disclose an existing test—as a prerequisite to the provision of insurance coverage.

The Genetic Non-Discrimination Act was opposed by the insurance industry and, upon its passage, then-attorney general Jody Wilson-Raybould stated she believed the law may be unconstitutional. [45] The provisions of the law, as they applied to provincially regulated industries, were challenged by the government of Quebec before the Quebec Court of Appeal, which held them unconstitutional. On July 10, 2020, the Supreme Court of Canada reversed the decision and upheld the law in a 5–4 split ruling. [46]

United Kingdom

The Equality Act 2010 prohibits the use of genetic information for employment decisions such as hiring and promotions. [47] While no formal law exists banning the use of genetic information for insurance policy decisions, the Government of the United Kingdom and the Association of British Insurers voluntarily entered a moratorium from 2014 to 2019 to refrain from using genetic information with regards to insurance. [48]

Malawi

Malawi is the only country in Africa that has enacted any laws regarding genetic discrimination. Malawi's National Health Sciences Research Committee adopted the policy requirements of the Science and Technology Act No.16 of 2003. [49]

Australia

In Australia, genetic information is less likely to influence health insurance coverage decisions as health insurance is "community rated", meaning that all individuals pay the same amount regardless of their history or genetic makeup. [50] However, genetic test results can be used by life insurance companies to deny cover, increase the cost of premiums, or place exclusions on cover. Since 2008, the amount of insurance applications with attached genetic test results has increased by 90%. [51] Although the community rating for health insurance allows for a more even distribution of risk and cost to consumers, life insurance companies are legally allowed to "underwrite" when evaluating the genetic risks of applicants; essentially, those with higher risk could potentially be charged higher premiums. [51] Life insurance companies can require individuals to report genetic testing results if they have already been tested, but cannot force individuals to take genetic tests. [52] These companies are able to require individuals to disclose genetic testing results from research and direct-to-consumer tests. [52]

Research in Australia demonstrated that life insurance discrimination deters people from participating in research and pursuing clinical genetic testing. [53] [54] In 2017, the Parliamentary Joint Committee on Corporations and Financial Services conducted an inquiry into the life insurance industry. In its 2018 report, [55] the Committee recommended an urgent ban on the use of genetic test results by life insurers, and that the Australian government maintain a watching brief to consider whether legislation was required in future.

In 2019, the Financial Services Council, the industry body for Australian life insurers, introduced a voluntary, partial, moratorium on using genetic test results for applications up to certain financial limits. [56] [57] The moratorium is self-regulated, with no government oversight.

In 2020, the Australian Genetics and Life Insurance Moratorium: Monitoring the Effectiveness and Response (A-GLIMMER) project was funded by the Australian Government Medical Research Futures Fund Genomics Health Futures Mission. [58] [59] The project was designed to evaluate the effectiveness of the moratorium in addressing genetic discrimination in Australia, from various stakeholder perspectives.

The project conducted research with consumers, [60] health professionals, [61] [62] genetic researchers and financial services personnel. It also conducted a policy analysis of the moratorium compared with the recommendations made by the Parliamentary Committee in 2018, finding that the moratorium did not meet the expectations of the recommendations. [63] The A-GLIMMER project concluded on 30 June 2023. It published its findings in a report, [64] which found that genetic discrimination continues to occur in Australia, and continues to deter individuals from pursuing genetic testing and participating in genetic research. The report concluded that the moratorium is inadequate to address and prevent genetic discrimination in life insurance, and should be replaced with a legislative model of prohibition. The Project recommended that: [64]

1. The Australian Government amend the Disability Discrimination Act 1992 (Cth) ('the Act') to prohibit insurers from using genetic or genomic test results to discriminate between applicants for risk-rated insurance, and consider amendments to the regulation of financial services to ensure insurers are subject to a positive duty to not discriminate.

2. The Australian Government allocate responsibility and appropriate resources to the Australian Human Rights Commission ('AHRC') to enforce, promote, educate and support individuals and all relevant stakeholders to understand and meet the new legal obligations under the Act. The AHRC should consult with a range of genetics and genomics experts and stakeholders to achieve this goal.

The Australian government is considering the recommendations in the report. The Assistant Treasurer and Minister for Financial Services, Stephen Jones, made a statement that [65] "We don't want people to avoid having genetic tests which could detect life threatening conditions because of a fear it may affect access to insurance. Early detection can lead to life saving interventions. That's in everyone's interest."

Argentina

Genetic discrimination is a rising issue in Argentina. [66] Health plans discriminate against those who have disabilities or who have genetic conditions. [67] In the past decade, however, National Law 26689 was passed providing patients with the right to not experience discrimination as a result of genetic conditions. [67]

Global instruments

The Universal Declaration on the Human Genome and Human Rights (1997), the International Declaration on Human Genetic Data (2003) [68] and the Universal Declaration on Bioethics and Human Rights (2005) [69] are global instruments drawn up by the International Bioethics Committee of UNESCO.

Genetic testing in the workplace

Some people have genes that make them more susceptible to developing a disease as a result of an occupational exposure. For example, workers with beryllium sensitivity and chronic beryllium disease are more likely to carry the gene HLA-DPB1 than workers without these conditions. [70] By offering optional genetic testing to workers and allowing only the workers to see their own results, employers could protect genetically susceptible individuals from certain occupational diseases. A beryllium manufacturing company initiated a pilot program to test prospective workers for the HLA-DPB1 gene at a university-based laboratory. The company paid for the testing and counseling but received results that did not identify which workers had the gene. [70]

In 1991, the American Medical Association Council on Ethical and Judicial Affairs suggested that the following five conditions must be satisfied in order for genetic screening by an employer to be appropriate: [70]

Several occupational health screening measures similar to genetic testing are already taking place. For example, in 1978, DuPont reported testing African American applicants for sickle cell trait and restricted these workers from exposure to nitro and amino compounds. [71] However, research indicates that workers or applicants would not take advantage of genetic testing due to fear of discrimination. A 1995 poll of the general public found that over 85% are concerned about access to use of genetic information by insurers and employers. [72] Likewise, in the case of the beryllium manufacturer described above, so few workers participated in the genetic testing that the company decided instead to pursue an "enhanced preventive model of workplace controls." [70]

Race

Researchers emphasize that race is not a scientifically valid concept and cannot accurately describe biological variation. [73] [74] Attempts to do using genetics may lead down a slippery slope toward scientific racism, the pseudoscientific practice of justifying racism using empirical evidence. [75] Though the human genome is extremely complex, humans share 99.9% of their DNA and differences among people cannot be attributed to social categories of race. [73] [76]

Some cases, however, have found statistical evidence of genetic differences between human populations, such as mutations within the Duffy blood group. [77] Yet research looking at 109 genetic markers across 16 populations by Guido Barbujani "does not suggest that the racial subdivision of our species reflects any major discontinuity in our genome". [78] As genomic research continues to investigate human genetic variation on a large scale, racial genetic discrimination remains a concern for many. [79]

Linking genetic conditions and treatments to race

State governments in the United States have attempted to combat racial discrimination by barring instances of discrimination by insurers that involve linking specific genetic conditions to race, such as the sickle cell trait in African Americans. Further, therapeutic interventions or treatments based on genetic variants associated with race can sometimes be inaccurate and lead to negative health outcomes. [79] An example of this has been doctors prescribing an improper dosage of a drug called warfarin prescribed to African American populations, despite research disproving they require a higher dose than white populations. [79] The medical community recognizes that genetic variants—such as predisposition to drug metabolism among others—make up only one facet of a person's health, which is also impacted by their environment and lifestyle. [80]

Genetic privacy

In addition, many individuals are concerned with their genetic privacy and worry that they will face discrimination based on their genetic information. [81] These worries may include loss of confidentiality, risk of information being shared with insurance providers, risk of genetic samples being used without their consent, and health-based discrimination more broadly. [81]

Genomic biobanks

Contributing to genomic biobanks can be an additional source of concern for minority populations. Biobanks are collections of biological samples which can include blood, tissue, or DNA from many people. Despite the utility of biobanks to furthering genomic research, minority groups fear that their samples may be used improperly or even be used to strike down an entire culture. [82] Such was the case when genetic samples were taken from the Havasupai people, a Native American tribe in Arizona. They consented for their samples to provide insight into the prevalence of diabetes in their community, but did not consent to them to investigate links to schizophrenia or provide evolutionary genetic analysis to discredit the tribe's origin beliefs. [82] Misuse of genetic data may create long-lasting distrust towards the medical community.

Diversity in genomics

Some efforts have been made to use genetic testing for reconciliation projects involving people of African descent, which attempt to make social reparations based upon genetic genealogy. [83] Though genetic ancestry testing can be a valuable source of information for those seeking connections to their heritage or recognize a new identity, African Americans may feel coerced into genetic testing or unknowingly face discrimination. [83] Participants also have very little control over how their data will be used, including within the medical sphere or the criminal justice system. [83] As such, increased circulation of genetic genealogical data may be harmful for African Americans. [83]

As minority populations are hesitant to contribute their DNA to genomic research, there continues to be a lack of inclusive health information being disseminated and incorporated in medical treatments. Genomic research has been predominantly based upon DNA samples with European heritage, which fails to holistically and accurately describe the complexity of all people's genetics. [84]

Other confounding factors related to diversity such as age, gender, or socioeconomic status may also influence genetic discrimination in addition to race. [79]

According to Jonathan Roberts and his colleagues, the media evokes irrational fear among the public about advances in genetic techniques. [85] In a recent study, participants who were prompted to convey their attitudes about unfamiliar scientific concepts relating to genetics ultimately drew conclusions based on examples from popular culture. [85]

Genoism is a neologism coined by Andrew Niccol, director and writer of the 1997 film Gattaca , used to describe unethical and illegal genetic discrimination. Predictions of physical and mental performance are computed via genetics from DNA collected from hair, fingernails, skin flakes, spit swabs, eyelashes, etc. Upon birth, a number of genetically induced characteristics are calculated: physical and intellectual capacity, life expectancy, probable successful diseases, and likely causes of death, all determined via blood samples and genetic testing. Job interviews, health insurance purchasing, and even potential dates can be sized up according to the perceived quality of the person's DNA due to advancements in genome sequencing. This put an ironic twist to Darwin's sexual selection for good genes. According to the movie, "We now have discrimination down to a science."

My father was right. It didn't matter how much I lied on my resume. My real resume was in my cells. Why should anybody invest all that money to train me when there were a thousand other applicants with a far cleaner profile? Of course, it's illegal to discriminate, 'genoism' it's called. But no one takes the law seriously. If you refuse to disclose, they can always take a sample from a door handle or a handshake, even the saliva on your application form. If in doubt, a legal drug test can just as easily become an illegal peek at your future in the company.

— Vincent Freeman (Ethan Hawke), Gattaca , 1997

See also

Related Research Articles

<span class="mw-page-title-main">Genetic counseling</span> Advising those affected by or at risk of genetic disorders

Genetic counseling is the process of investigating individuals and families affected by or at risk of genetic disorders to help them understand and adapt to the medical, psychological and familial implications of genetic contributions to disease. This field is considered necessary for the implementation of genomic medicine. The process integrates:

<span class="mw-page-title-main">Genetic testing</span> Medical test

Genetic testing, also known as DNA testing, is used to identify changes in DNA sequence or chromosome structure. Genetic testing can also include measuring the results of genetic changes, such as RNA analysis as an output of gene expression, or through biochemical analysis to measure specific protein output. In a medical setting, genetic testing can be used to diagnose or rule out suspected genetic disorders, predict risks for specific conditions, or gain information that can be used to customize medical treatments based on an individual's genetic makeup. Genetic testing can also be used to determine biological relatives, such as a child's biological parentage through DNA paternity testing, or be used to broadly predict an individual's ancestry. Genetic testing of plants and animals can be used for similar reasons as in humans, to gain information used for selective breeding, or for efforts to boost genetic diversity in endangered populations.

<span class="mw-page-title-main">Pharmacogenomics</span> Study of the role of the genome in drug response

Pharmacogenomics, often abbreviated "PGx," is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of a patient affects their response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response, by correlating DNA mutations with pharmacokinetic, pharmacodynamic, and/or immunogenic endpoints.

<span class="mw-page-title-main">Ancestry-informative marker</span>

In population genetics, an ancestry-informative marker (AIM) is a single-nucleotide polymorphism that exhibits substantially different frequencies between different populations. A set of many AIMs can be used to estimate the proportion of ancestry of an individual derived from each population.

Predictive medicine is a field of medicine that entails predicting the probability of disease and instituting preventive measures in order to either prevent the disease altogether or significantly decrease its impact upon the patient.

Public health genomics is the use of genomics information to benefit public health. This is visualized as more effective preventive care and disease treatments with better specificity, tailored to the genetic makeup of each patient. According to the Centers for Disease Control and Prevention (U.S.), Public Health genomics is an emerging field of study that assesses the impact of genes and their interaction with behavior, diet and the environment on the population's health.

<span class="mw-page-title-main">Biobank</span> Repository of biological samples used for research

A biobank is a type of biorepository that stores biological samples for use in research. Biobanks have become an important resource in medical research, supporting many types of contemporary research like genomics and personalized medicine.

Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.

Genomic counseling is the process by which a person gets informed about his or her genome often in the setting of elective genetic and genomic testing. In contrast to genetic counseling, which focuses on Mendelian diseases and typically involves person-to-person communication with a genetic counselor or other medical genetics expert, genomic counseling is not limited to currently clinically relevant information. It is often based on genomic information that is of interest for the informed person, such as increased risk for common complex disease that has actionable components, genetically determined non-disease related traits, or recreational forms of information and genetic genealogy data. An individual's response to certain medications/drugs based on their pharmacogenomic profile may be provided.

<span class="mw-page-title-main">Exome sequencing</span> Sequencing of all the exons of a genome

Exome sequencing, also known as whole exome sequencing (WES), is a genomic technique for sequencing all of the protein-coding regions of genes in a genome. It consists of two steps: the first step is to select only the subset of DNA that encodes proteins. These regions are known as exons—humans have about 180,000 exons, constituting about 1% of the human genome, or approximately 30 million base pairs. The second step is to sequence the exonic DNA using any high-throughput DNA sequencing technology.

Biobank ethics refers to the ethics pertaining to all aspects of biobanks. The issues examined in the field of biobank ethics are special cases of clinical research ethics.

Return of results is a concept in research ethics which describes the extent of the duty of a researcher to reveal and explain the results of research to a research participant.

Privacy for research participants is a concept in research ethics which states that a person in human subject research has a right to privacy when participating in research. Some typical scenarios this would apply to include, or example, a surveyor doing social research conducts an interview with a participant, or a medical researcher in a clinical trial asks for a blood sample from a participant to see if there is a relationship between something which can be measured in blood and a person's health. In both cases, the ideal outcome is that any participant can join the study and neither the researcher nor the study design nor the publication of the study results would ever identify any participant in the study. Thus, the privacy rights of these individuals can be preserved.

Genetic testing is the analysis of human genes, proteins, and certain metabolites, in order to detect inherited disease-related propensities. These tests can predict the risk of disease in adults, as well as establish prenatal and infant prognoses. The benefits can be substantial, but so can the risks. The possible adverse consequences of genetic tests include discrimination in employment and health insurance and breaches of privacy. Government policies are therefore needed to assure the proper use of genetic tests. The first piece of federal legislation came into effect in 2000.

Dynamic consent is an approach to informed consent that enables on-going engagement and communication between individuals and the users and custodians of their data. It is designed to address the many issues that are raised by the use of digital technologies in research and clinical care that enable the wide-scale use, linkage, analysis and integration of diverse datasets and the use of AI and big data analyses. These issues include how to obtain informed consent in a rapidly-changing environment; growing expectations that people should know how their data is being used; increased legal and regulatory requirements for the management of secondary use of data in biobanks and other medical research infrastructure. The approach started to be implemented in 2007 by an Italian group who introduced the ways to have an ongoing process of interaction between researcher and participant where "technology now allows the establishment of dynamic participant–researcher partnerships." The use of digital interfaces in this way was first described as 'Dynamic Consent' in the EnCoRe project. Dynamic Consent therefore describes a personalised, digital interface that enables two-way communication between participants and researchers and is a practical example of how software can be developed to give research participants greater understanding and control over how their data is used. It also enables clinical trial managers, researchers and clinicians to know what type of consent is attached to the use of data they hold and to have an easy way to seek a new consent if the use of the data changes. It is able to support greater accountability and transparency, streamlining consent processes to enable compliance with regulatory requirements.

Genetic privacy involves the concept of personal privacy concerning the storing, repurposing, provision to third parties, and displaying of information pertaining to one's genetic information. This concept also encompasses privacy regarding the ability to identify specific individuals by their genetic sequence, and the potential to gain information on specific characteristics about that person via portions of their genetic information, such as their propensity for specific diseases or their immediate or distant ancestry.

Elective genetic and genomic testing are DNA tests performed for an individual who does not have an indication for testing. An elective genetic test analyzes selected sites in the human genome while an elective genomic test analyzes the entire human genome. Some elective genetic and genomic tests require a physician to order the test to ensure that individuals understand the risks and benefits of testing as well as the results. Other DNA-based tests, such as a genealogical DNA test do not require a physician's order. Elective testing is generally not paid for by health insurance companies. With the advent of personalized medicine, also called precision medicine, an increasing number of individuals are undertaking elective genetic and genomic testing.

DNA encryption is the process of hiding or perplexing genetic information by a computational method in order to improve genetic privacy in DNA sequencing processes. The human genome is complex and long, but it is very possible to interpret important, and identifying, information from smaller variabilities, rather than reading the entire genome. A whole human genome is a string of 3.2 billion base paired nucleotides, the building blocks of life, but between individuals the genetic variation differs only by 0.5%, an important 0.5% that accounts for all of human diversity, the pathology of different diseases, and ancestral story. Emerging strategies incorporate different methods, such as randomization algorithms and cryptographic approaches, to de-identify the genetic sequence from the individual, and fundamentally, isolate only the necessary information while protecting the rest of the genome from unnecessary inquiry. The priority now is to ascertain which methods are robust, and how policy should ensure the ongoing protection of genetic privacy.

Privacy laws vary from state to state within the United States of America. Several states have recently passed new legislation that adapt to changes in cyber security laws, medical privacy laws, and other privacy related laws. State laws are typically extensions of existing United States federal laws, expanding them or changing the implementation of the law.

Medical genetic ethics is a field in which the ethics of medical genetics is evaluated. Like the other field of medicine, medical genetics also face ethical issues.

References

  1. ↑ Ajunwa I (2014). "Genetic Testing Meets Big Data: Torts and Contract Law Issues". Ohio State Law Journal. 75. SSRN   2460891.
  2. ↑ Ajunwa I (2016). "Genetic Data and Civil Rights". Harvard Civil Rights- Civil Liberties Law Review. 51. doi:10.2139/ssrn.2460897. SSRN   2460897.
  3. ↑ Annas G (2003). "Genism, Racism, and the Prospect of Genetic Genocide". Archived from the original on 2011-07-26. Retrieved 2008-07-31.
  4. 1 2 Executive Office of the President (27 April 2007). "Statement of Administration policy" (PDF). Office of Management and Budget. Archived from the original (PDF) on 2018-08-21.
  5. 1 2 Braverman G, Shapiro ZE, Bernstein JA (June 2018). "Ethical Issues in Contemporary Clinical Genetics". Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 2 (2): 81–90. doi:10.1016/j.mayocpiqo.2018.03.005. PMC   6124343 . PMID   30225437.
  6. ↑ Joly Y, Ngueng Feze I, Song L, Knoppers BM (2017-03-06). "Normative Approaches to Address Genetic Discrimination: Placebo or Panacea?". Trends in Genetics. Rochester, NY. SSRN   2911199.
  7. ↑ "GINAhelp.org – Your GINA Resource". ginahelp.org. Retrieved 2019-10-21.
  8. 1 2 3 Field RI, Orlando AW, Rosoff AJ (February 2021). "Genetics and COVID-19: How to Protect the Susceptible". Trends in Genetics. 37 (2): 106–108. doi:10.1016/j.tig.2020.08.019. PMC   7456262 . PMID   32943209.
  9. ↑ Keim B (21 May 2008). "Genetic Discrimination by Insurers, Employers Becomes a Crime". WIRED. Retrieved 2018-11-05.
  10. ↑ Feldman EA (June 2012). "The Genetic Information Nondiscrimination Act (GINA): public policy and medical practice in the age of personalized medicine". Journal of General Internal Medicine. 27 (6): 743–6. doi:10.1007/s11606-012-1988-6. PMC   3358381 . PMID   22314637.
  11. ↑ Hudson KL, Holohan MK, Collins FS (June 2008). "Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008". The New England Journal of Medicine. 358 (25): 2661–3. doi: 10.1056/nejmp0803964 . PMID   18565857.
  12. 1 2 McGuire AL, Majumder MA (January 2009). "Two cheers for GINA?". Genome Medicine. 1 (1): 6. doi: 10.1186/gm6 . PMC   2651591 . PMID   19348693.
  13. ↑ Otlowski M, Taylor S, Bombard Y (2012-09-12). "Genetic discrimination: international perspectives". Annual Review of Genomics and Human Genetics. 13 (1): 433–54. doi:10.1146/annurev-genom-090711-163800. PMID   22607273.
  14. ↑ Gilbert N (2015-06-25). "Why the 'devious defecator' case is a landmark for US genetic-privacy law". Nature. doi: 10.1038/nature.2015.17857 . S2CID   182253502.
  15. ↑ Harmon A (24 February 2008). "Insurance Fears Lead Many to Shun DNA Tests". The New York Times. Retrieved 2018-11-05.
  16. ↑ Dupras C, Song L, Saulnier KM, Joly Y (2018-06-08). "Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination". Frontiers in Genetics. 9: 202. doi: 10.3389/fgene.2018.00202 . PMC   6002493 . PMID   29937773.
  17. 1 2 Bélisle-Pipon JC, Vayena E, Green RC, Cohen IG (August 2019). "Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries". Nature Medicine. 25 (8): 1198–1204. doi:10.1038/s41591-019-0534-z. PMID   31388181. S2CID   199448885.
  18. ↑ "What is genetic discrimination?". Genetics Home Reference. Retrieved 2018-11-05.
  19. ↑ Center for Drug Evaluation and Research (2019-12-20). "Direct-to-Consumer Tests". FDA.
  20. ↑ "Behind at-home DNA testing companies sharing genetic data with third parties". CBS News. 2 August 2018. Retrieved 2018-11-05.
  21. ↑ Allyse MA, Robinson DH, Ferber MJ, Sharp RR (January 2018). "Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing". Mayo Clinic Proceedings. 93 (1): 113–120. doi: 10.1016/j.mayocp.2017.11.001 . PMID   29304915.
  22. ↑ Charbonneau J, Nicol D, Chalmers D, Kato K, Yamamoto N, Walshe J, Critchley C (March 2020). "Public reactions to direct-to-consumer genetic health tests: A comparison across the US, UK, Japan and Australia". European Journal of Human Genetics. 28 (3): 339–348. doi:10.1038/s41431-019-0529-8. PMC   7029038 . PMID   31645768.
  23. ↑ Hoglund-Shen A (July 2017). "Direct-to-Consumer Genetic Testing, Gamete Donation, and the Law: DTC Genetic Testing, Gamete Donation, and the Law". Family Court Review. 55 (3): 472–484. doi:10.1111/fcre.12288.
  24. 1 2 Tozzo P, Caenazzo L (September 2020). "The Skeleton in the Closet: Faults and Strengths of Public Versus Private Genetic Biobanks". Biomolecules. 10 (9): 1273. doi: 10.3390/biom10091273 . PMC   7564942 . PMID   32899386.
  25. 1 2 Hendricks-Sturrup RM, Cerminara KL, Lu CY (December 2020). "A Qualitative Study to Develop a Privacy and Nondiscrimination Best Practice Framework for Personalized Wellness Programs". Journal of Personalized Medicine. 10 (4): 264. doi: 10.3390/jpm10040264 . PMC   7761887 . PMID   33287396.
  26. ↑ Vayena E, Mauch F (July 2012). "[Personal genomics: are we debating the right Issues?]". Praxis. 101 (15): 961–4. doi:10.1024/1661-8157/a001008. PMID   22811328.
  27. 1 2 Ducharme J (26 July 2018). "A Major Drug Company Now Has Access to 23andMe's Genetic Data. Should You Be Concerned?". Time. Retrieved 2021-04-07.
  28. ↑ King J (7 November 2019). ""It's not Personal" — DNA, Privacy, and Direct to Consumer Genetic Testing". cyberlaw.stanford.edu. Retrieved 2021-04-07.
  29. ↑ Lanton III R, Garfinkel C (10 September 2018). "What Is Genetic Discrimination, and How Can It Affect Us?". Specialty Pharmacy Times. September/October. 9 (6). Retrieved 2021-04-07.
  30. ↑ Li H, Liu SM, Yu XH, Tang SL, Tang CK (May 2020). "Coronavirus disease 2019 (COVID-19): current status and future perspectives". International Journal of Antimicrobial Agents. 55 (5): 105951. doi:10.1016/j.ijantimicag.2020.105951. PMC   7139247 . PMID   32234466.
  31. ↑ CDC (2020-02-11). "COVID-19 and Your Health". Centers for Disease Control and Prevention. Retrieved 2021-04-06.
  32. ↑ Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. (July 2020). "New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis". BMC Medicine. 18 (1): 216. doi: 10.1186/s12916-020-01673-z . PMC   7360473 . PMID   32664879.
  33. ↑ Godri Pollitt KJ, Peccia J, Ko AI, Kaminski N, Dela Cruz CS, Nebert DW, et al. (May 2020). "COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission". Human Genomics. 14 (1): 17. doi: 10.1186/s40246-020-00267-3 . PMC   7214856 . PMID   32398162.
  34. ↑ Cohen J, Rodgers YV (December 2020). "Contributing factors to personal protective equipment shortages during the COVID-19 pandemic". Preventive Medicine. 141: 106263. doi:10.1016/j.ypmed.2020.106263. PMC   7531934 . PMID   33017601.
  35. ↑ Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. (May 2020). "Fair Allocation of Scarce Medical Resources in the Time of Covid-19". The New England Journal of Medicine. 382 (21): 2049–2055. doi: 10.1056/NEJMsb2005114 . PMID   32202722.
  36. 1 2 "COVID-19 and Disability-Based Discrimination in Health Care". www.americanbar.org. Retrieved 2021-04-21.
  37. ↑ News Division (2020-06-26). "OCR Resolves Complaint with Tennessee After it Revises its Triage Plans to Protect Against Disability Discrimination". HHS.gov. Retrieved 2021-04-21.
  38. ↑ Chen B, McNamara DM (September 2020). "Disability Discrimination, Medical Rationing and COVID-19". Asian Bioethics Review. 12 (4): 511–518. doi:10.1007/s41649-020-00147-x. PMC   7471485 . PMID   32901207.
  39. ↑ News Division (2020-04-08). "OCR Reaches Early Case Resolution With Alabama After It Removes Discriminatory Ventilator Triaging Guidelines". HHS.gov. Retrieved 2021-04-21.
  40. ↑ "COVID-19 Medical Rationing & Facility Visitation Policies – Center for Public Representation". www.centerforpublicrep.org. Retrieved 2021-04-21.
  41. ↑ "Genetic discrimination". American Medical Association. Retrieved 2021-04-07.
  42. ↑ Hollenstein M, Naccache D, Rønne PB, Ryan PY, Weil R, Yifrach-Stav O (2020-08-01). "Preservation of DNA Privacy During the Large Scale Detection of COVID-19". arXiv: 2007.09085 [cs.CR].
  43. ↑ Carr D, Adler S, Winig BD, Montez JK (March 2020). "Equity First: Conceptualizing a Normative Framework to Assess the Role of Preemption in Public Health". The Milbank Quarterly. 98 (1): 131–149. doi:10.1111/1468-0009.12444. PMC   7077775 . PMID   31951048.
  44. 1 2 "Public Bill (Senate) S-201 (42–1) – Royal Assent – Genetic Non-Discrimination Act – Parliament of Canada" . Retrieved 2017-05-04.
  45. ↑ Tasker JP (March 8, 2017). "Liberal backbenchers defy cabinet wishes and vote to enact genetic discrimination law". CBC News. Retrieved 10 July 2020.
  46. ↑ Stefanovich O (10 July 2020). "Supreme Court of Canada upholds genetic non-discrimination law". CBC News. Retrieved 10 July 2020.
  47. ↑ "Equality Act 2010". www.legislation.gov.uk. Retrieved 2018-11-05.
  48. ↑ "Concordat and Moratorium on Genetics and Insurance" (PDF). Association of British Insurers (ABI).
  49. ↑ Joly Y, Feze IN, Song L, Knoppers BM (May 2017). "Comparative Approaches to Genetic Discrimination: Chasing Shadows?". Trends in Genetics. 33 (5): 299–302. doi:10.1016/j.tig.2017.02.002. PMID   28365141.
  50. ↑ "Genetic discrimination | NHMRC". www.nhmrc.gov.au. Retrieved 2019-11-14.
  51. 1 2 Barlow-Stewart K, Liepins M, Doble A, Otlowski M (September 2018). "How are genetic test results being used by Australian life insurers?". European Journal of Human Genetics. 26 (9): 1248–1256. doi:10.1038/s41431-018-0198-z. PMC   6117272 . PMID   29891881.
  52. 1 2 Tiller J, Otlowski M, Lacaze P (2017-12-13). "Should Australia Ban the Use of Genetic Test Results in Life Insurance?". Frontiers in Public Health. 5: 330. doi: 10.3389/fpubh.2017.00330 . PMC   5733354 . PMID   29322039.
  53. ↑ Tiller, Jane; Morris, Susan; Rice, Toni; Barter, Krystal; Riaz, Moeen; Keogh, Louise; Delatycki, Martin B.; Otlowski, Margaret; Lacaze, Paul (January 2020). "Genetic discrimination by Australian insurance companies: a survey of consumer experiences". European Journal of Human Genetics. 28 (1): 108–113. doi:10.1038/s41431-019-0426-1. ISSN   1476-5438. PMC   6906286 . PMID   31281182.
  54. ↑ Tiller, Jane; Keogh, Louise; Wake, Samantha; Delatycki, Martin; Otlowski, Margaret; Lacaze, Paul (2018). "Genetics, Insurance and Professional Practice: Survey of the Australasian Clinical Genetics Workforce". Frontiers in Public Health. 6: 333. doi: 10.3389/fpubh.2018.00333 . ISSN   2296-2565. PMC   6277853 . PMID   30542646.
  55. ↑ "Report". www.aph.gov.au. Retrieved 2023-07-05.
  56. ↑ Genetic Tests and Life Insurance Key Facts
  57. ↑ FSC Announces Moratorium on Genetic Tests for Life Insurance to Start in July 2019
  58. ↑ Tiller, Jane; Winship, Ingrid; Otlowski, Margaret Fa; Lacaze, Paul A. (March 2021). "Monitoring the genetic testing and life insurance moratorium in Australia: a national research project". The Medical Journal of Australia. 214 (4): 157–159.e1. doi:10.5694/mja2.50922. hdl: 11343/298213 . ISSN   1326-5377. PMID   33550592. S2CID   225484738.
  59. ↑ Tiller, Jane; McInerney-Leo, Aideen; Belcher, Andrea; Boughtwood, Tiffany; Gleeson, Penny; Delatycki, Martin; Barlow-Stewart, Kristine; Winship, Ingrid; Otlowski, Margaret; Keogh, Louise; Lacaze, Paul (2021-05-21). "Study protocol: the Australian genetics and life insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project". BMC Medical Ethics. 22 (1): 63. doi: 10.1186/s12910-021-00634-2 . ISSN   1472-6939. PMC   8138092 . PMID   34020638.
  60. ↑ Tiller, Jane; Bakshi, Andrew; Dowling, Grace; Keogh, Louise; McInerney-Leo, Aideen; Barlow-Stewart, Kristine; Boughtwood, Tiffany; Gleeson, Penny; Delatycki, Martin B.; Winship, Ingrid; Otlowski, Margaret; Lacaze, Paul (2023-05-11). "Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing". European Journal of Human Genetics. 32 (3): 286–294. doi: 10.1038/s41431-023-01373-1 . ISSN   1476-5438. PMC   10923945 . PMID   37169978. S2CID   258637737.
  61. ↑ Tiller, Jane M.; Keogh, Louise A.; McInerney-Leo, Aideen M.; Belcher, Andrea; Barlow-Stewart, Kristine; Boughtwood, Tiffany; Gleeson, Penny; Dowling, Grace; Prince, Anya; Bombard, Yvonne; Joly, Yann; Delatycki, Martin; Winship, Ingrid M.; Otlowski, Margaret; Lacaze, Paul (August 2022). "A step forward, but still inadequate: Australian health professionals' views on the genetics and life insurance moratorium". Journal of Medical Genetics. 59 (8): 817–826. doi:10.1136/jmedgenet-2021-107989. ISSN   1468-6244. PMID   34544841. S2CID   235238642.
  62. ↑ Dowling, Grace; Tiller, Jane; McInerney-Leo, Aideen; Belcher, Andrea; Haining, Casey; Barlow-Stewart, Kristine; Boughtwood, Tiffany; Gleeson, Penny; Delatycki, Martin B.; Winship, Ingrid; Otlowski, Margaret; Jacobs, Chris; Keogh, Louise; Lacaze, Paul (November 2022). "Health professionals' views and experiences of the Australian moratorium on genetic testing and life insurance: A qualitative study". European Journal of Human Genetics. 30 (11): 1262–1268. doi:10.1038/s41431-022-01150-6. ISSN   1476-5438. PMC   9626480 . PMID   35902697.
  63. ↑ Tiller, Jane; Lacaze, Paul; Otlowski, Margaret (2022-12-13). "The Australian moratorium on genetics and life insurance: evaluating policy compared to Parliamentary recommendations regarding genetic discrimination". Public Health Research & Practice. 32 (4): 3242235. doi:10.17061/phrp3242235. ISSN   2204-2091. PMID   36509687. S2CID   254582496.
  64. 1 2 Tiller, Jane; Gleeson, Penny; McInerney-Leo, Aideen M.; Keogh, Louise; Nowak, Kristen; Barlow-Stewart, Kristine; Boughtwood, Tiffany; Delatycki, Martin B.; Winship, Ingrid; Otlowski, Margaret; Lacaze, Paul (2023-06-29). Final Stakeholder Report of the Australian Genetics and Life Insurance Moratorium: Monitoring the Effectiveness and Response (A-GLIMMER) Project (Report). Monash University. doi:10.26180/23564538.
  65. ↑ Borys, Stephanie (2023-06-29). "Australians skipping genetic screening tests out of fear it will affect life insurance coverage". ABC News. Retrieved 2023-07-05.
  66. ↑ Valdovinos CF (2005-11-01). Growth, inequality, and social equity in Argentina (Report). pp. 1–4.
  67. 1 2 Penchaszadeh VB (July 2015). "Ethical issues in genetics and public health in Latin America with a focus on Argentina". Journal of Community Genetics. 6 (3): 223–30. doi:10.1007/s12687-015-0217-5. PMC   4524838 . PMID   25666434.
  68. ↑ "UNESCO adopts international declaration on human genetic data". European Commission. Retrieved 1 June 2023.
  69. ↑ "UN panel warns against 'designer babies' and eugenics in 'editing' of human DNA | UN News". news.un.org. 2015-10-05. Retrieved 2023-06-01.
  70. 1 2 3 4 DeBord DG, Schulte P, Butler MA, McCanlies E, Reutman S, Ruder A, et al. (Genetics Working Group) (November 2009). Tuchman RJ (ed.). Genetics in the Workplace: Implications for Occupational Safety and Health (PDF). National Institute for Occupational Safety and Health (NIOSH) (Report). Washington, D.C.: Centers for Disease Control and Prevention, U.S. Department for Health and Human Services.
  71. ↑ Brandt-Rauf PW, Brandt-Rauf SI (2004). "Genetic testing in the workplace: ethical, legal, and social implications". Annual Review of Public Health. 25: 139–53. doi: 10.1146/annurev.publhealth.25.101802.123012 . PMID   15015916.
  72. ↑ Miller PS (June 2001). "Genetic discrimination in the workplace". Genetics in Medicine. 3 (3): 165–6. doi: 10.1097/00125817-200105000-00001 . PMID   11388754.
  73. 1 2 Nelson R (2019-06-25). "Racism in science: the taint that lingers". Nature. 570 (7762): 440–441. Bibcode:2019Natur.570..440N. doi: 10.1038/d41586-019-01968-z .
  74. ↑ "AAPA Statement on Race & Racism". physanth.org. Retrieved 2021-04-27.
  75. ↑ Meloni M (2017). "Scientific Racism". The Wiley-Blackwell Encyclopedia of Social Theory. American Cancer Society. pp. 1–3. doi:10.1002/9781118430873.est0324. ISBN   978-1-118-43087-3.
  76. ↑ Condit C (2007). "How culture and science make race "genetic": motives and strategies for discrete categorization of the continuous and heterogeneous". Literature and Medicine. 26 (1): 240–68. doi:10.1353/lm.2008.0000. PMID   18290369. S2CID   33203830.
  77. ↑ McManus KF, Taravella AM, Henn BM, Bustamante CD, Sikora M, Cornejo OE (March 2017). Hoekstra HE (ed.). "Population genetic analysis of the DARC locus (Duffy) reveals adaptation from standing variation associated with malaria resistance in humans". PLOS Genetics. 13 (3): e1006560. doi: 10.1371/journal.pgen.1006560 . PMC   5365118 . PMID   28282382.
  78. ↑ Barbujani G, Magagni A, Minch E, Cavalli-Sforza LL (April 1997). "An apportionment of human DNA diversity". Proceedings of the National Academy of Sciences of the United States of America. 94 (9): 4516–9. Bibcode:1997PNAS...94.4516B. doi: 10.1073/pnas.94.9.4516 . PMC   20754 . PMID   9114021.
  79. 1 2 3 4 Haga SB (January 2017). "Chapter 2 - Overview of Policy, Ethical, and Social Considerations in Genomic and Personalized Medicine". In David SP (ed.). Genomic and Precision Medicine (third ed.). Boston: Academic Press. pp. 19–43. doi:10.1016/b978-0-12-800685-6.00005-9. ISBN   978-0-12-800685-6.
  80. ↑ Dumitrescu, R. G. (2017-01-01), Verma, Mukesh; Barh, Debmalya (eds.), "Chapter 4 - Cancer Genetic Screening and Ethical Considerations for Precision Medicine", Progress and Challenges in Precision Medicine, Academic Press, pp. 79–100, doi:10.1016/b978-0-12-809411-2.00004-0, ISBN   978-0-12-809411-2 , retrieved 2021-03-22
  81. 1 2 Clayton EW, Halverson CM, Sathe NA, Malin BA (2018-10-31). "A systematic literature review of individuals' perspectives on privacy and genetic information in the United States". PLOS ONE. 13 (10): e0204417. Bibcode:2018PLoSO..1304417C. doi: 10.1371/journal.pone.0204417 . PMC   6209148 . PMID   30379944.
  82. 1 2 Abadie, Roberto; Heaney, Kathleen (2015). ""We can wipe an entire culture": fears and promises of DNA biobanking among Native Americans". Dialectical Anthropology. 39 (3): 305–320. doi:10.1007/s10624-015-9391-4. ISSN   0304-4092. S2CID   142335757.
  83. 1 2 3 4 Nelson A (September 2018). "The social life of DNA: racial reconciliation and institutional morality after the genome". The British Journal of Sociology. 69 (3): 522–537. doi: 10.1111/1468-4446.12607 . PMID   30328106.
  84. ↑ "Lack Of Diversity In Genetic Databases Hampers Research". NPR.org. Retrieved 2021-04-08.
  85. 1 2 Roberts J, Archer L, DeWitt J, Middleton A (May 2019). "Popular culture and genetics; friend, foe or something more complex?". European Journal of Medical Genetics. 62 (5): 368–375. doi:10.1016/j.ejmg.2018.12.005. PMC   6626485 . PMID   30590173.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.